Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
This article follows our recent announcement that Vivani has entered into an agreement with Novo Nordisk to evaluate our semaglutide implant, NPM-139, for chronic weight management
During the first month, researchers monitored appetite, food cravings, gastrointestinal symptoms, body weight, and treatment tolerability while participants adjusted to this investigational GLP-3 triple hormone receptor agonist
By proactively managing hunger signals, many users achieve weight loss and, for some, better weight maintenance afterward
Still GLP-1 friendly
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
US$ 24.29
US$ 23.33
US$ 29.69
